Lexaria Extends Agreement to Advance Drug Delivery Technology Evaluation
I'm PortAI, I can summarize articles.
Lexaria Bioscience Corp. has extended its Material Transfer Agreement with a pharmaceutical company to further evaluate its DehydraTECH technology in a pre-clinical setting. This collaboration aims to enhance the efficacy and safety of its technology, with final results expected by the end of 2025. The latest analyst rating for LEXX stock is a Buy with a $4.00 price target. Lexaria is known for its innovative drug delivery platforms and holds 54 patents worldwide, with a current market cap of $24.67M.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments